ALEMBIC PHARMACEUTICALS
|
ALEMBIC PHARMACEUTICALS Last 5 Year Financial Ratios History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 29.68 | 31.33 | 17.40 | 26.50 | 58.33 |
| CEPS(Rs) | 43.78 | 45.20 | 31.41 | 41.09 | 66.05 |
| DPS(Rs) | 11.00 | 11.00 | 8.00 | 10.00 | 14.00 |
| Book NAV/Share(Rs) | 264.10 | 245.14 | 222.36 | 266.47 | 257.80 |
| Tax Rate(%) | 17.70 | 2.53 | 3.55 | 16.70 | 18.52 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 15.03 | 14.97 | 12.53 | 16.48 | 27.44 |
| EBIT Margin(%) | 11.78 | 11.05 | 7.16 | 12.12 | 25.66 |
| Pre Tax Margin(%) | 10.60 | 10.14 | 6.27 | 11.79 | 25.37 |
| PAT Margin (%) | 8.72 | 9.89 | 6.05 | 9.82 | 20.67 |
| Cash Profit Margin (%) | 12.90 | 14.26 | 10.92 | 15.22 | 24.07 |
| Performance Ratios | |||||
| ROA(%) | 8.28 | 9.93 | 5.15 | 7.34 | 16.95 |
| ROE(%) | 11.63 | 13.40 | 7.12 | 10.11 | 26.91 |
| ROCE(%) | 13.51 | 13.42 | 7.44 | 11.25 | 26.28 |
| Asset Turnover(x) | 0.95 | 1.00 | 0.85 | 0.75 | 0.82 |
| Sales/Fixed Asset(x) | 1.67 | 1.70 | 1.79 | 1.97 | 2.31 |
| Working Capital/Sales(x) | 3.98 | 3.84 | 4.44 | 4.64 | 3.93 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.60 | 0.59 | 0.56 | 0.51 | 0.43 |
| Receivable days | 66.32 | 60.69 | 59.84 | 39.75 | 41.06 |
| Inventory Days | 107.54 | 91.38 | 99.60 | 106.49 | 90.48 |
| Payable days | 164.40 | 150.62 | 148.04 | 173.51 | 187.92 |
| Valuation Parameters | |||||
| PER(x) | 31.31 | 31.35 | 28.50 | 27.97 | 16.55 |
| PCE(x) | 21.22 | 21.73 | 15.79 | 18.04 | 14.61 |
| Price/Book(x) | 3.52 | 4.01 | 2.23 | 2.78 | 3.74 |
| Yield(%) | 1.18 | 1.12 | 1.61 | 1.35 | 1.45 |
| EV/Net Sales(x) | 2.90 | 3.15 | 1.82 | 2.85 | 3.59 |
| EV/Core EBITDA(x) | 18.43 | 20.39 | 14.49 | 16.37 | 12.35 |
| EV/EBIT(x) | 24.65 | 28.50 | 25.45 | 23.53 | 13.99 |
| EV/CE(x) | 3.03 | 3.74 | 2.06 | 2.09 | 2.78 |
| M Cap / Sales | 2.74 | 3.10 | 1.72 | 2.75 | 3.52 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 7.12 | 10.19 | 6.54 | -1.62 | 17.10 |
| Core EBITDA Growth(%) | 9.27 | 35.24 | -23.09 | -41.02 | 27.66 |
| EBIT Growth(%) | 14.23 | 69.98 | -37.06 | -53.53 | 34.77 |
| PAT Growth(%) | -5.49 | 80.07 | -34.35 | -53.27 | 39.23 |
| EPS Growth(%) | -5.26 | 80.07 | -34.35 | -54.56 | 32.66 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.23 | 0.09 | 0.15 | 0.12 | 0.10 |
| Current Ratio(x) | 1.67 | 2.07 | 1.78 | 1.63 | 1.89 |
| Quick Ratio(x) | 0.76 | 0.99 | 0.88 | 0.75 | 0.93 |
| Interest Cover(x) | 9.98 | 12.24 | 8.07 | 36.27 | 86.40 |
| Total Debt/Mcap(x) | 0.07 | 0.02 | 0.07 | 0.04 | 0.03 |
Compare Financial Ratios of peers of ALEMBIC PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| ALEMBIC PHARMACEUTICALS | ₹20,255.7 Cr | 3% | 3.1% | -0.7% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹403,580.0 Cr | 0.6% | -0.4% | 4.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹180,069.0 Cr | -2.2% | 1.7% | 47.3% | Stock Analytics | |
| CIPLA | ₹119,919.0 Cr | -0.2% | -1.4% | -1.9% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹115,310.0 Cr | 2.5% | 4.8% | 12.2% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹104,402.0 Cr | -2.6% | -8.1% | -4.9% | Stock Analytics | |
ALEMBIC PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| ALEMBIC PHARMACEUTICALS | 3% |
3.1% |
-0.7% |
| SENSEX | -1.4% |
0.7% |
2.4% |
You may also like the below Video Courses
